![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Glenmark Pharmaceuticals Gets Indian Approval for Favipiravir as a COVID-19 Treatment
Glenmark Pharmaceuticals Gets Indian Approval for Favipiravir as a COVID-19 Treatment
![India_shape.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/India_shape.jpg?t=1600823036&width=430)
Glenmark Pharmaceuticals has earned approval in India for emergency use of its influenza antiviral favipiravir for the treatment of mild-to-moderate COVID-19.
The Mumbai-based drugmaker plans to market the antiviral as FabiFlu. The drug was only approved for restricted emergency use.
Glenmark is also conducting phase 3 trials of favipiravir as a COVID-19 monotherapy in nine hospitals across India.
Upcoming Events
-
21Oct